Loading stock data…
GRCE
$2.33+0.03 (+1.30%)
Grace Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Grace Therapeutics, Inc. in the Healthcare sector is trading at $2.33. Wall Street consensus targets $5.89 (2 analysts), implying a +152.6% move over the next 12 months. The stock is currently near its 52-week low of $1.79, remaining 30.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +152.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.33
Potential Downside
0%
Whystock Fair Value$2.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.21%
Volume
Today's trading volume
151,557
Recent News
Sector Update: Health Care Stocks Edge Lower Late Afternoon
Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the Stat
We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, Grace...
This Grace Therapeutics Insider Increased Their Holding By 12% Last Year
Insiders were net buyers of Grace Therapeutics, Inc.'s ( NASDAQ:GRCE ) stock during the past year. That is, insiders...
We Think Grace Therapeutics (NASDAQ:GRCE) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Grace Therapeutics, Inc. (NASDAQ:GRCE) Is Expected To Breakeven In The Near Future
Grace Therapeutics, Inc. ( NASDAQ:GRCE ) is possibly approaching a major achievement in its business, so we would like...